Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Amishi Y Shah"'
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c777865947454d67bd544bb4094e3d5f
Autor:
Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in
Externí odkaz:
https://doaj.org/article/8affada371c5430f97f977800c38a734
Autor:
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang, Apostolia M. Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A. Yap, David S. Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y. Shah, Amado Zurita, Nizar M. Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin a
Externí odkaz:
https://doaj.org/article/0e41dd980da3400cb70f16af34c1c22a
Autor:
Joseph A. Moore, Michael J. Lehner, Simone Anfossi, Saumil Datar, Rebecca S. Tidwell, Matthew Campbell, Amishi Y. Shah, John F. Ward, Jose A. Karam, Christopher G. Wood, Lois L. Pisters, George A. Calin, Shi‐Ming Tu
Publikováno v:
BJUI Compass, Vol 4, Iss 1, Pp 81-87 (2023)
Abstract Objectives To investigate the utility of a novel serum miRNA biomarker panel to distinguish teratoma from nonmalignant necrotic/fibrotic tissues or nonviable tumours in patients with NSGCT undergoing post‐chemotherapy consolidation surgery
Externí odkaz:
https://doaj.org/article/4fdcd3926f9d47d19bbfd8f80ed57502
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Abstract Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitu
Externí odkaz:
https://doaj.org/article/eafab2babacd4730b744815d6b4763df
Autor:
Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh G. Hoang, Wei-Lien Wang, Jian Song, Lidia Lopez, Alex Andreev-Drakhlin, Arlene Siefker-Radtke, Xinqiao Zhang, William F. Benedict, Amishi Y. Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C. Guo, Bogdan Czerniak, Carmen Behrens, Luisa Soto, Vassiliki Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Jack Roth, Stephen Swisher, Ignacio Wistuba, John Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
The deficiency of MTAP, an enzyme of the adenine salvage pathway, occurs in some cancers. Here the authors perform a small cohort phase II clinical trial with metastatic MTAP-deficient urothelial cancer (UC) and show an increased overall response whe
Externí odkaz:
https://doaj.org/article/7a4eb434bab9460784c2152084c1035e
Autor:
Omar Alhalabi, Matthew T. Campbell, Lianchun Xiao, Ana C. Adriazola, Nathaniel R. Wilson, Arlene O. Siefker‐Radtke, Paul G. Corn, Amado Zurita, Eric Jonasch, Jianjun Gao, Mehrad Adibi, Ashish M. Kamat, Neema Navai, Louis L. Pisters, Colin Dinney, Surena F. Matin, Amishi Y. Shah
Publikováno v:
BJUI Compass, Vol 3, Iss 1, Pp 37-44 (2022)
Abstract Objectives Multimodal kidney‐preserving (MKP) strategies may be an option for patients with localised or locally advanced high‐risk upper tract urothelial carcinoma (UTUC) who have a relative contraindication for nephroureterectomy (NU).
Externí odkaz:
https://doaj.org/article/4bec1710d1984582ada90fc20a09d76b
Autor:
Matthew T. Campbell, Surena F. Matin, Alda L. Tam, Rahul A. Sheth, Kamran Ahrar, Rebecca S. Tidwell, Priya Rao, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Eric Jonasch, Jianjun Gao, Amado J. Zurita, Amishi Y. Shah, Sonali Jindal, Fei Duan, Sreyashi Basu, Hong Chen, Alexsandra B. Espejo, James P. Allison, Shalini S. Yadav, Padmanee Sharma
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Anti-CTLA4 therapy has not been comprehensively explored for the treatment of metastatic renal cell carcinoma (mRCC). Here, in a pilot study of anti-CTLA4 therapy with or without cryoablation in mRCC, the authors report that the combination is feasib
Externí odkaz:
https://doaj.org/article/204efb116032411484ebc80c52f409dc
Autor:
Paul V. Viscuse, Mario L. Marques-Piubelli, Meghan M. Heberton, Edwin Roger Parra, Amishi Y. Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L. Curry, Matthew T. Campbell
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from N
Externí odkaz:
https://doaj.org/article/55a10ccbe61c41a892852b9f573c314e
Autor:
Alexander D. Sherry, Tharakeswara K. Bathala, Suyu Liu, Bryan M. Fellman, Stephen G. Chun, Nikesh Jasani, B. Ashleigh Guadagnolo, Anuja Jhingran, Jay P. Reddy, Paul G. Corn, Amishi Y. Shah, Kelsey W. Kaiser, Amol J. Ghia, Daniel R. Gomez, Chad Tang
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:910-918
The benefit of local consolidative therapy (LCT) for oligometastasis across histologies remains uncertain. EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND; NCT03599765) is a randomized phase 2 basket trial evaluating the effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f210bcfdce82fa972bbaf61d6a7a872c
https://doi.org/10.1016/j.ijrobp.2022.05.023
https://doi.org/10.1016/j.ijrobp.2022.05.023